Scientists Develop Nano-medicine for Blood Cancer

A nano-medicine for drug-resistant blood cancer has been developed by scientists.

This is expected to dramatically improve the treatment of drug-resistant chronic myelogenous leukemia (CML), when used in combination with Imatinib, the standard drug for the disease.

Acute Lymphoblastic Leukemia - Incidence Causes Symptoms Diagnosis Treatment Prognosis
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.

In another significant invention, the 2006-founded Amrita Centre has devised a mechanism that can effectively prevent recurrence of glioma or brain tumour.

This deadly disease affects about four out of every 100,000 people in India. The life expectancy of high-grade glioma patients is about one to two years.

The two projects will be formally unveiled Sep 26 at Amritavarsham60, the 60th birthday celebrations of the hugging saint or Amma as she is popularly referred to by her devotees.

Leukemia / Blood Cancer
Leukemia is cancer of blood-forming tissues in the body.

CML annually affects approximately two out of every 100,000 Indians. Almost 40 per cent of these cases are resistant to Imatinib. For such patients, treatment options are extremely limited.

"What we have done at Amrita is to take a particular 'small-molecule inhibitor' class of anti-cancer drug, currently available in the market and encapsulate it into a protein nano-capsule," said Shantikumar Nair, the centre's director.

Blood Cancer Drug may Stop Spread of Breast Cancer Cells
Researchers at Mayo Clinic in Florida have discovered that a drug used to treat blood cancers may also stop the spread of invasive breast cancer.

"This allows the drug to be absorbed directly into the cancer cells circulating in the patient's bloodstream. This has a marked increase on its efficacy in killing cancer cells. Further, the circulation lifetime of the drug in the blood is increased, which also enhances its efficacy," he added.

The nano-encapsulated version of the drug has shown itself to be non-toxic in healthy mice in tests conducted by his department, and it has similarly demonstrated itself to be effective in tests involving blood samples of people with Imatinib-resistant CML.

Unique Virus-Derived Particles can Kill Blood Cancer Cells
Unique virus-derived particles can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects, a new study reveals.

Manzoor Koyakutty, professor at the Centre, says the next step is to evaluate its efficacy in fighting CML in mice. "If it continues to remain non-toxic and effective, we can move on to clinical trials," added the expert and drug co-inventor.

Source-IANS